《国家基本药物目录》与《WHO基本药物标准清单》中抗栓药物的比较与分析

Analysis of antithrombotic medicines between the National Essential Medicines List and the WHO Model List of Essential Medicines

目的:比较《国家基本药物目录》(2012年版、2018年版)与《WHO基本药物标准清单》(2017年版)中抗栓药物的异同,为进一步完善我国基本药物目录提供参考。方法:采用描述性分析的方法比较目录中抗栓药物的品种、数量、剂型、规格及相关标注的差异,对此类药物的目录特点、优劣及存在的问题进行分析。结果:与《WHO基本药物标准清单》相比,《国家基本药物目录》收录的抗栓药物品种更多,抗凝血药物的调入基本符合国际趋势,但抗血小板药物的调入与调出还有待更充足的循证证据支持;剂型、规格及相关标注情况还需进一步细化。结论:《国家基本药物目录》(2018年版)抗栓药物目录的合理性有所提高,但部分药物的调入与调出标准以及剂型、规格的规范化还有待进一步提高。《WHO基本药物标准清单》对我国持续修订和完善国家基本药物目录具有指导价值。

Objective:To understand the difference of antithrombotic medicines between the National Essential Medicines List(C-EML 2012 and C-EML 2018)and the WHO Essential Medicines Model List(WHO-EML 2017)in order to provide reference for the revision of C-EML in the future.Methods:The composition,classification,specific drugs,dosage form,drug specification and sign of list were compared by descriptive analysis.Results:Compared with the WHO-EML,C-EML 2018 contains more varieties of antithrombotic drugs,and the introduction of anticoagulant drugs is basically in line with the international trend.However,the introduction and removal of antiplatelet drugs remains to be supported by more evidence.And the dosage form,specification and sign of list need to be further refined.Conclusion:The rationality of C-EML 2018 has been improved,but the selection and removal of some medicines and the standardization of dosage forms and specifications need to be further improved.The WHO-EML has reference and guiding value for China to continuously revise and improve the national essential drugs list.